Neuroblastoma: Molecular Mechanisms and Therapeutic Interventions comprehensively reviews current concepts in molecular and histopathological mechanisms that influence the growth of human malignant neuroblastoma, along with exciting therapeutic interventions. This book features a broad collection of contributions from leading investigators in histopathology, molecular mechanisms, genetics, epigenetics, microRNAs, proteomics, and metabolism in controlling growth and death in neuroblastoma. Recent developments in therapeutic interventions for neuroblastoma are also covered extensively, including chapters on surgery, chemotherapy, targeted therapy and immunotherapy. This book is ideal for advanced undergraduate students, graduate students, medical students, postdoctoral fellows, and investigators with an interest in current molecular concepts and therapeutic interventions. Comprehensively covers the histopathological characterization, molecular mechanisms, and most recent therapeutic interventions in neuroblastoma Includes recent developments and therapeutic interventions for neuroblastoma, including chapters on surgery, chemotherapy, targeted therapy and immunotherapy Presents a broad scope that provides basic researchers, practitioners and students with the most current overview of recent advances
This book addresses neuroblastoma, a type of embryonic tumor derived from neural crest cells and one of the most frequent extra-cranial solid tumors in children. However, the term also describes a heterogeneous group of tumors, the prognosis of which can differ greatly according to age, stage and biology. Some forms undergo spontaneous regression, and some are cured by surgery alone or after chemo-reduction, while others exhibit extremely aggressive behavior. Their successful treatment is one of the best examples of tailored medicine, which involves close collaboration between pediatric surgeons, pediatric oncologists, radiologists, nuclear medicine specialists, biologists, oncogeneticists and radiotherapists. The book pursues a unique approach, as it combines most essential insights from all of these fields, together with key information regarding epidemiology, physiopathology and palliative care. The respective chapters were written by the leading international experts on neuroblastoma, and present the latest advances in terms of research, surgical approaches and medical treatments. The book offers an invaluable resource to all pediatric surgeons, pediatricians, oncologists, students, researchers and all others involved in neuroblastoma management who want to benefit from their colleagues’ expertise.
Neuroblastoma is a medical enigma. As a childhood neoplasm arising from neural crest cells, it is characterized by diverse clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. Although clinical outcome can be predicted to a large extent by the stage of disease and the age at diagnosis, an in-depth understanding of its clinico-pathological behavior, now greatly aided by sophisticated molecular genetic profiling, will improve diagnostic precision and refine risk-based therapies. Comprehensive international efforts have advanced our understanding of tumor biology and improved the clinical management of children with neuroblastoma. This book reviews our current understanding of the genes and biological pathways that contribute to neuroblastoma pathogenesis, modern risk-based treatment approaches for these patients, and recent advances in biologically based therapy. It provides a concise up-to-date reference for practitioners, students, and researchers.
Neuroblastoma (NBL) is the most common extracranial solid tumor of childhood, with about 700 new cases of neuroblastoma seen each year in the United States. The 5-year survival rate for children with high-risk NBL is only 50-60%, and this survival rate has not improved over the last 10 years. High-risk patients receive multimodality treatment, including chemotherapy, surgery, radiation therapy, biologic therapy and immunotherapy, all of which are associated with significant morbidity. Recent years have seen many advances in treatment of neuroblastoma, including therapeutic MIBG, immunotherapy, and personalized targeted therapy based on the genetic alterations seen in the tumor. The primary objective of this book is to provide the readers with a comprehensive review of neuroblastoma, from clinical aspects and the currently available treatment to recent advancements and future directions in the field of NBL treatment. The topics and chapters have been compiled keeping in mind a diverse group of readers in different areas of specialty such as pediatric oncology, surgery, radiation oncology, and immunology, as well as physician scientists and basic researchers working in the field of neuroblastoma.
|Author||: Ernest E. Lack,Armed Forces Institute of Pathology (U.S.),Universities Associated for Research and Education in Pathology|
|Publisher||: Amer Registry of Pathology|
|Release Date||: 1997|
|Pages||: 468 pages|
Neuroblastoma is a tumor derived from the sympathetic nervous system. It is the most common extracranial solid tumor occurring in children and exhibits a marked variability in outcome when the disease is categorized by clinical (e.g. age or stage) and biologic characteristics. This book gives an introduction into the clinical features of progressive neuroblastoma and focuses on molecular-targeted therapies and immunotherapies of this disease. It has become increasingly clear that MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog) holds a key position in neuroblastic transformation and gene expression in normal and transformed cells. In the 14 chapters important topics such as genomic alterations in neuroblastoma and strategies for indirect molecular targeting of MYCN are discussed. Two chapters, for example, review apoptotic pathways and proapoptotic molecular targets in neuroblastoma, one focusing on the p53 pathway and the extrinsic and intrinsic pathways of apoptosis. Other chapters cover topics related to immunology in neuroblastoma, such as immune regulation in neuroblastoma, immunotherapy related to passive and active vaccination approaches and additional immunotherapy in the treatment of progressive disease. This volume will be essential reading for all clinicians and basic researchers who are involved in delivering health care to patients with progressive neuroblastoma.
|Author||: Helen May North-Root|
|Release Date||: 1974|
|Pages||: 244 pages|